The three COVID-19 vaccines authorized for use in the United States are not “well-matched” against the BA.2 virus subvariant, which has recently been estimated to have become dominant in the country, U.S. regulators said on April 6.
“While currently available vaccines are not well-matched to the dominant circulating variant—which is the Omicron BA.2 sublineage—we do still have some residual vaccine effectiveness,” particularly against severe outcomes, Dr. Dorian Fink, an official with the Food and Drug Administration (FDA), said.